Research Library

The top resource for free research, white papers, reports, case studies, magazines, and eBooks.

Share Your Content with Us
on for readers like you. LEARN MORE
Examining RET Fusions: How Real-World Data (RWD) Can Support a Tumor-Agnostic Era

Request Your Free White Paper Now:

"Examining RET Fusions: How Real-World Data (RWD) Can Support a Tumor-Agnostic Era"

On May 23, 2017, the FDA approved pembrolizumab for adult and pediatric patients with unresectable/metastatic microsatellite instability-high or mismatch repair deficient tumors. This approval marked the first targeted therapy to receive a tumor-agnostic approval and paved the way for a new paradigm in clinical oncology.

To date, there are many biomarkers, preclinical drugs, and FDA-approved therapies that are of intense interest due to their potential applications in a tumor-agnostic setting. NTRK inhibitors larotrectinib and entrectinib received tumor-agnostic approval for solid tumors harboring NTRK fusions in November 2018. RET inhibitor selpercatinib received tumor-agnostic FDA approval in September 2022 for adult patients with locally advanced/metastatic solid tumors harboring RET rearrangements.

This white paper from NeoGenomics explores the novel tumor-agnostic approach of testing for RET-rearranged tumors, identifying both the challenges and prospects of a new pan-tumor indication.

Offered Free by: NeoGenomics
See All Resources from: NeoGenomics

Recommended for Professionals Like You: